These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34844772)

  • 21. Overview of immune abnormalities in lysosomal storage disorders.
    Rigante D; Cipolla C; Basile U; Gulli F; Savastano MC
    Immunol Lett; 2017 Aug; 188():79-85. PubMed ID: 28687233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement.
    Nascimbeni F; Dionisi Vici C; Vespasiani Gentilucci U; Angelico F; Nobili V; Petta S; Valenti L;
    Dig Liver Dis; 2020 Apr; 52(4):359-367. PubMed ID: 31902560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysosomal storage diseases--the horizon expands.
    Boustany RM
    Nat Rev Neurol; 2013 Oct; 9(10):583-98. PubMed ID: 23938739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis.
    Marques ARA; Di Spiezio A; Thießen N; Schmidt L; Grötzinger J; Lüllmann-Rauch R; Damme M; Storck SE; Pietrzik CU; Fogh J; Bär J; Mikhaylova M; Glatzel M; Bassal M; Bartsch U; Saftig P
    Autophagy; 2020 May; 16(5):811-825. PubMed ID: 31282275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autophagy in astrocytes: a novel culprit in lysosomal storage disorders.
    Di Malta C; Fryer JD; Settembre C; Ballabio A
    Autophagy; 2012 Dec; 8(12):1871-2. PubMed ID: 23047468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CNS-directed gene therapy for lysosomal storage diseases.
    Sands MS; Haskins ME
    Acta Paediatr; 2008 Apr; 97(457):22-7. PubMed ID: 18339183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.
    Solomon M; Muro S
    Adv Drug Deliv Rev; 2017 Sep; 118():109-134. PubMed ID: 28502768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
    Li M
    Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lysosomal storage diseases and the blood-brain barrier.
    Begley DJ; Pontikis CC; Scarpa M
    Curr Pharm Des; 2008; 14(16):1566-80. PubMed ID: 18673198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Advanced Strategies for the Treatment of Lysosomal Diseases Affecting the Central Nervous System.
    Gigliobianco MR; Di Martino P; Deng S; Casadidio C; Censi R
    Curr Pharm Des; 2019; 25(17):1933-1950. PubMed ID: 31566121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease.
    Abasolo I; Seras-Franzoso J; Moltó-Abad M; Díaz-Riascos V; Corchero JL; Pintos-Morell G; Schwartz S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 May; 13(3):e1684. PubMed ID: 33314628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autophagy, mitochondria and cell death in lysosomal storage diseases.
    Kiselyov K; Jennigs JJ; Rbaibi Y; Chu CT
    Autophagy; 2007; 3(3):259-62. PubMed ID: 17329960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones.
    Wei H; Kim SJ; Zhang Z; Tsai PC; Wisniewski KE; Mukherjee AB
    Hum Mol Genet; 2008 Feb; 17(4):469-77. PubMed ID: 17989065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defective collagen proteostasis and matrix formation in the pathogenesis of lysosomal storage disorders.
    Settembre C; Cinque L; Bartolomeo R; Di Malta C; De Leonibus C; Forrester A
    Matrix Biol; 2018 Oct; 71-72():283-293. PubMed ID: 29870768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploiting the Potential of
    Rigon L; De Filippis C; Napoli B; Tomanin R; Orso G
    Biomedicines; 2021 Mar; 9(3):. PubMed ID: 33800050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders.
    Placci M; Giannotti MI; Muro S
    Adv Drug Deliv Rev; 2023 Jun; 197():114683. PubMed ID: 36657645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of induced pluripotent stem cells in lysosomal storage diseases.
    Kido J; Nakamura K; Era T
    Mol Cell Neurosci; 2020 Oct; 108():103540. PubMed ID: 32828964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lysosomal Proteins as a Therapeutic Target in Neurodegeneration.
    Mc Donald JM; Krainc D
    Annu Rev Med; 2017 Jan; 68():445-458. PubMed ID: 28099085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lysosomal storage diseases: current therapies and future alternatives.
    Leal AF; Espejo-Mojica AJ; Sánchez OF; Ramírez CM; Reyes LH; Cruz JC; Alméciga-Díaz CJ
    J Mol Med (Berl); 2020 Jul; 98(7):931-946. PubMed ID: 32529345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat.
    Hay Mele B; Rossetti F; Cubellis MV; Monticelli M; Andreotti G
    Genes (Basel); 2024 Feb; 15(3):. PubMed ID: 38540351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.